Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 811 to 820 of 2607 total matches.

Choice of Cephalosporin

   
The Medical Letter on Drugs and Therapeutics • Nov 30, 1990  (Issue 832)
; between 1% and 10% of adult patients with penicillin allergy will develop allergic reactions when given ...
Since the last Medical Letter review of cephalosporin antibiotics (volume 25, page 57, 1983), many new cephalosporins have become available in the USA.
Med Lett Drugs Ther. 1990 Nov 30;32(832):107-10 |  Show IntroductionHide Introduction

Drugs for Head Lice

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024  (Issue 1704)
, but especially in elementary school children. In most cases, transmission occurs by head-to-head contact.1 ...
Pediculosis capitis (head lice infestations) occur in all age groups, but especially in elementary school children. In most cases, transmission occurs by head-to-head contact. Pharmacologic treatment is recommended for persons with live lice or eggs (nits) within 1 cm of the scalp. Topical pediculicides should be tried first. Oral therapy is occasionally required for refractory infestations.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):89-92   doi:10.58347/tml.2024.1704a |  Show IntroductionHide Introduction

Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • Nov 05, 2018  (Issue 1559)
-aooe (Aimovig), which targets the CGRP receptor, was the first.1 Fremanezumab (Ajovy ...
The FDA has approved two subcutaneously injected calcitonin gene-related peptide (CGRP) antagonists, fremanezumab-vfrm (Ajovy – Teva) and galcanezumab-gnlm (Emgality – Lilly), for migraine prevention in adults. Fremanezumab and galcanezumab are the second and third subcutaneously injected monoclonal antibodies that target the CGRP pathway to be approved by the FDA for this indication; erenumab-aooe (Aimovig), which targets the CGRP receptor, was the first.
Med Lett Drugs Ther. 2018 Nov 5;60(1559):177-80 |  Show IntroductionHide Introduction

Drugs for Hepatitis C Virus Infection

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024  (Issue 1714)
persons in the US had hepatitis C between 2017 and 2020.1 Guidelines from the American Association ...
About 2.5 million persons in the US had hepatitis C between 2017 and 2020. Guidelines from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) on management of hepatitis C virus (HCV) infection were updated in 2023.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):169-74   doi:10.58347/tml.2024.1714a |  Show IntroductionHide Introduction

Drugs for Breast Cancer

   
Treatment Guidelines from The Medical Letter • Jan 01, 2005  (Issue 29)
from The Medical Letter ® 1 Drugs for Breast Cancer In addition to surgery and radiation therapy, a variety ...
In addition to surgery and radiation therapy, a variety of drugs are used both singly and in combination to treat breast cancer. This article summarizes the principles of adjuvant therapy and treatment for metastatic disease. A summary of individual drugs and their adverse effects begins on page 3.
Treat Guidel Med Lett. 2005 Jan;3(29):1-6 |  Show IntroductionHide Introduction

Drugs for Bipolar Disorder

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024  (Issue 1699)
Drugs for Bipolar Disorder Volume 66 (Issue 1699) April 1, 2024 Bipolar disorder is characterized ...
Bipolar disorder is characterized by episodes of mania, hypomania, and depression. Recurrences of manic or (more frequently) depressive symptoms are common. About 15-20% of patients with bipolar disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54   doi:10.58347/tml.2024.1699a |  Show IntroductionHide Introduction

Drugs for Inflammatory Bowel Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
. Guidelines for treatment of UC and CD have been updated in recent years.1,2 AMINOSALICYLATES ...
Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12   doi:10.58347/tml.2023.1680a |  Show IntroductionHide Introduction

Interferon Beta-1b for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 1993  (Issue 900)
relapsing-remitting MS compared placebo, 1.6 million international units (IU) of interferon beta-1b, and 8 ...
Interferon β-1b (Betaseron - Berlex), an analog of human interferon β pro-duced in E. coli, may soon be approved by the US Food and Drug Administration for treatment of relapsing-remitting multiple sclerosis (MS), the most common form of the disease (G Mitchell, Med Clin North Am, 77:231, 1993).
Med Lett Drugs Ther. 1993 Jul 9;35(900):61-2 |  Show IntroductionHide Introduction

Cephalosporins for Patients with Penicillin Allergy

   
The Medical Letter on Drugs and Therapeutics • Dec 24, 2012  (Issue 1406)
a penicillin.1 HISTORY OF ALLERGY — Patients with a history of an IgE-mediated reaction to a penicillin ...
Only a small minority of patients who say they are allergic to penicillin will have a reaction if they take a penicillin.
Med Lett Drugs Ther. 2012 Dec 24;54(1406):101 |  Show IntroductionHide Introduction

Regorafenib (Stivarga) for Metastatic Colorectal Cancer and GIST (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 2013  (Issue 1415)
(GIST). Grade 3 or higher adverse effects occur in about 50% of patients. o 1. A Grothey et al ...
Regorafenib (Stivarga – Bayer), a multikinase inhibitor, has been approved by the FDA for treatment of patients with metastatic colorectal cancer previously treated with multiple other regimens specified in the labeling. It has also been approved for use in treatment-refractory, locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST).
Med Lett Drugs Ther. 2013 Apr 29;55(1415):36 |  Show IntroductionHide Introduction